2015 Fiscal Year Final Research Report
Establishment of the treatment strategy in the urothelial carcinoma cell lines which targeted the apoptotic marker.
| Project/Area Number |
26861294
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | アポトーシス / 抗癌剤 / 予後因子 |
|---|
| Outline of Final Research Achievements |
ABT-737 which was a repressor for apoptotic protein Bcl-2/Bcl-xL showed cell injury effect and migration suppressant effect and the combination effect with the anticancer agent on urothelial carcinoma cell lines. The expression of apoptotic related protein was shown to be the poor prognostic factor for the intravesical relapsed patient after upper urinary tract urothelial carcinoma treatment. Therefore, it is suggested that ABT-737 could become the new treatment choice for urothelial carcinoma.
|
| Free Research Field |
尿路上皮癌
|
